STOCK TITAN

Pliant Therapeutics (PLRX) Stock News

PLRX NASDAQ

Pliant Therapeutics, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. Its lead program, PLN-101095, is an oral small-molecule dual-selective inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors, including immune checkpoint inhibitor-refractory advanced or metastatic disease.

Company updates commonly cover Phase 1 and Phase 1b oncology data, scientific-conference presentations, combination studies with pembrolizumab, financial results, and healthcare investor-conference participation. Pliant also describes preclinical platform work using integrin receptor-binding molecules for tissue-specific delivery and internalization of drug payloads, including programs directed to skeletal muscle cells, adipocytes, and renal cells.

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) reported a narrower third-quarter 2026 net loss as development of its oncology and drug-delivery programs continued. Net loss was $24.377 million, or $0.39 per share, versus $26.301 million, or $0.43 per share, a year earlier. General and administrative expenses fell to $7.810 million from $10.331 million; research and development expenses were approximately unchanged at $17.9 million.

Pliant said FORTIFY enrollment was ahead of schedule, with interim data expected in 2027. The Phase 1b expansion evaluates PLN-101095 with pembrolizumab in checkpoint-inhibitor-resistant cancers. Its RNA delivery platform showed more than 75% target gene knockdown at eight weeks in non-human primates. Pliant plans initial programs in neuromuscular diseases and rare cardiomyopathies and expects funding to support operations to mid-2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
-
Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) presented preclinical findings and new clinical biomarker analyses for PLN-101095 at the Society for Immunotherapy of Cancer annual meeting.

Preclinical work combining blockade of integrins αvβ8 and αvβ1 with anti-PD-1 treatment showed improved anti-tumor activity and survival. In the Phase 1 trial, early increases in immune activation biomarkers during PLN-101095 monotherapy were associated with subsequent clinical response after pembrolizumab was added; this was an association, not proof of causation.

The ongoing FORTIFY Phase 1a/1b trial evaluates the combination in advanced or metastatic solid tumors resistant to immune checkpoint inhibitors. Its Phase 1b expansion is enrolling cohorts with non-small cell lung cancer, tumors with high tumor mutational burden, or clear cell renal cell carcinoma. Treatment starts with PLN-101095 alone before pembrolizumab is added.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
-
Rhea-AI Summary

Pliant Therapeutics (PLRX) announced two PLN-101095 poster presentations at the Society for Immunotherapy of Cancer meeting, taking place November 4–8, 2026. The meeting is at the Phoenix Convention Center in Phoenix, Arizona.

The November 6 poster addresses integrin targeting and immune checkpoint inhibition, with results obtained through a National Cancer Institute collaboration. The November 7 poster concerns plasma biomarkers and response to immune checkpoint inhibition in patients receiving PLN-101095. FORTIFY, the ongoing Phase 1a/1b trial, is enrolling its Phase 1b cohorts in non-small cell lung cancer, tumors with high tumor mutational burden, and clear cell renal cell carcinoma. Treatment starts with PLN-101095 alone before pembrolizumab is added.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
Rhea-AI Summary

Pliant Therapeutics (PLRX) appointed Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA), bringing experience in RNA-based drug discovery and delivery. Blanchette most recently served as Chief Scientific Officer at Switch Therapeutics, where he advanced two programs into studies supporting applications to begin human testing.

In connection with his employment, Pliant granted Blanchette options to purchase 300,000 common shares on October 19, 2026. The exercise price equals the stock’s closing price that day. The options vest over four years, subject to continued employment, with 25% vesting after one year and the remainder in 36 equal monthly installments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
Rhea-AI Summary

Pliant Therapeutics (PLRX) announced a poster presentation on its ongoing FORTIFY trial at the ESMO Congress on October 23, 2026. The Phase 1b indication expansion trial is enrolling patients whose solid tumors have resisted immune checkpoint inhibitors. The poster covers PLN-101095 in combination with pembrolizumab and will be presented by Timothy A. Yap in Madrid.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
-
Rhea-AI Summary

Pliant Therapeutics (PLRX) appointed David Raben, M.D., as Chief Medical Officer, with his employment beginning on September 30, 2026. Raben brings more than 30 years of oncology research, clinical care and drug-development experience and most recently served as Chief Medical Officer at Bicara Therapeutics. Pliant expects trial readouts in 2027 as it advances PLN-101095, its oncology program.

In connection with his employment, Pliant granted Raben options to purchase 575,000 common shares. The exercise price equals the stock’s closing price on the grant date, and vesting depends on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) reported that the U.S. FDA has granted Fast Track designation to PLN-101095, an oral dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential treatment of solid tumors resistant to immune checkpoint inhibitors (ICIs).

PLN-101095 is being studied in the Phase 1a/1b FORTIFY trial (NCT06270706), with data expected in 2027. According to Pliant Therapeutics, Fast Track status may allow more frequent FDA interactions, rolling New Drug Application submissions and eligibility for priority review if criteria are met.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
-
Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) reported second quarter 2026 results and a corporate update, highlighting strong, ahead-of-schedule enrollment in FORTIFY, its Phase 1a/1b trial of PLN-101095 with pembrolizumab in ICI-refractory solid tumors, targeting up to 102 patients across NSCLC, ccRCC and high tumor mutational burden cohorts. Updated Phase 1 monotherapy biomarker data showed coordinated increases in IFN-γ, CXCL9 and granzyme-B only in responding patients, supporting a potential tumor microenvironment shift. Pliant advanced its integrin-targeted siRNA delivery platform and plans further detail in 2H 2026. Q2 2026 R&D and G&A expenses fell to $16.7M and $7.1M, respectively, with net loss narrowing to $22.4M and cash, cash equivalents and short-term investments of $159.6M, expected to fund operations into 2H 2028. The company also added oncology leaders Flavia Borellini and Robert Iannone to its board.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
-
Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) announced the appointment of Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to its Board of Directors, adding extensive global oncology drug development, regulatory and operational experience as the company advances its integrin-based pipeline, including PLN-101095.

According to Pliant Therapeutics, Dr. Borellini brings more than 25 years of leadership across Acerta Pharma, AstraZeneca and Genentech, where she led development and approvals for multiple targeted therapies. Dr. Iannone contributes over two decades of clinical development and regulatory leadership from Jazz Pharmaceuticals, Immunomedics, AstraZeneca and Merck.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
management
Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) will present new data on PLN-101095 at the 2026 ASCO Annual Meeting in Chicago from May 29 to June 2, 2026.

The poster highlights FORTIFY, a Phase 1b indication expansion trial in ICI-refractory advanced or metastatic solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
conferences

FAQ

What is the current stock price of Pliant Therapeutics (PLRX)?

Pliant Therapeutics (PLRX) last closed at $0.6932.

What is the market cap of Pliant Therapeutics (PLRX)?

The market cap of Pliant Therapeutics (PLRX) is approximately $43.2M.